PDPHF (Egetis Therapeutics AB) Net Margin %: -705.35% (As of Mar. 2026)

What is Egetis Therapeutics AB Net Margin %?

Egetis Therapeutics AB PDPHF 24 Net Margin % is -705.35% as of Mar. 2026. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 947 Biotechnology companies, Egetis Therapeutics AB ranks worse than 72.54% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Egetis Therapeutics AB's Net Income for the three months ended in Mar. 2026 was $-10.14 Mil. Egetis Therapeutics AB's Revenue for the three months ended in Mar. 2026 was $1.44 Mil. Therefore, Egetis Therapeutics AB's net margin for the quarter that ended in Mar. 2026 was -705.35%.

The historical rank and industry rank for Egetis Therapeutics AB's Net Margin % or its related term are showing as below:

PDPHF' s Net Margin % Range Over the Past 10 Years
Min: -861.33 Med: -548.88 Max: -74.4
Current: -592.09

PDPHF's Net Margin % is ranked worse than
72.54% of 947 companies
in the Biotechnology industry
Industry Median: -89.56 vs PDPHF: -592.09

Egetis Therapeutics AB (OTCPK:PDPHF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Egetis Therapeutics AB Net Margin % Related Terms

Egetis Therapeutics AB Net Margin % Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Net Margin % Chart

Egetis Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

-272.83

-861.35

-567.57

-745.27

-548.91

Egetis Therapeutics AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															-495.45	-535.02	-473.65	-668.74	-705.35

PDPHF vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egetis Therapeutics AB Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Net Margin % falls into.

Save Embed

24GF Score

Egetis Therapeutics AB PDPHF

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Egetis Therapeutics AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Egetis Therapeutics AB's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-36.854	/	6.714
	=	-548.91 %

Egetis Therapeutics AB's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-10.143	/	1.438
	=	-705.35 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -705.35% mean?

Egetis Therapeutics AB (PDPHF) has a Net Margin % of -705.35% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Egetis Therapeutics AB and its competitors. According to the industry distribution chart, Egetis Therapeutics AB ranks #687 out of 947 companies in the Biotechnology industry, placing it in the top 72.5%.

Is Egetis Therapeutics AB's Net Margin % too high?

Egetis Therapeutics AB's current Net Margin % is -705.35%. Based on the distribution chart, Egetis Therapeutics AB ranks #687 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Egetis Therapeutics AB's Net Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #687 out of 947 companies for Net Margin %. This places Egetis Therapeutics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Net Margin % is -705.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Egetis Therapeutics AB stock overvalued right now?

Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current Net Margin % is -705.35%. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current Net Margin % is -705.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued. The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for PDPHF:

Net Margin %: -705.35%
GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:VICO OSTO:HNSA OSTO:FLERIE OSTO:BINV OSTO:SANION XSAT:HAMLET B OSTO:GENO XSAT:CURAS OSTO:XSPRAY OSTO:MVIR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges EGTX:Sweden 0ABW:UK P0F:Germany

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46

Website https://www.egetis.com

Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

24GF Score

Get the complete analysis for PDPHF

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64

Price

$0.64

GF Value

View PDPHF Analysis

See Net Margin % data for all stocks →